

Jessica Zucman-Rossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5118071/publications.pdf>

Version: 2024-02-01

394
papers

50,040
citations

3333

91
h-index

1713

213
g-index

420
all docs

420
docs citations

420
times ranked

51377
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 616-626.	6.1	106
2	Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. <i>Hepatology</i> , 2022, 75, 997-1011.	3.6	16
3	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. <i>Journal of Hepatology</i> , 2022, 76, 343-352.	1.8	30
4	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100390.	2.6	15
5	TGF β -induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer. <i>Hepatology Communications</i> , 2022, 6, 1157-1171.	2.0	9
6	Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 540-551.	3.2	23
7	Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. <i>Liver International</i> , 2022, 42, 492-506.	1.9	20
8	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. <i>Lancet Oncology</i> , The, 2022, 23, 161-171.	5.1	36
9	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). <i>Clinical Nutrition</i> , 2022, 41, 610-619.	2.3	8
10	A framework for fibrolamellar carcinoma research and clinical trials. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 328-342.	8.2	23
11	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. <i>JHEP Reports</i> , 2022, 4, 100481.	2.6	3
12	Deleting the β -catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. <i>Journal of Hepatology</i> , 2022, 77, 424-435.	1.8	17
13	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 612-624.	5.1	66
14	Structure, Dynamics, and Impact of Replication Stress-Induced Structural Variants in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 1470-1481.	0.4	0
15	LIM Homeobox-2 Suppresses Hallmarks of Adult and Pediatric Liver Cancers by Inactivating MAPK/ERK and Wnt/Beta-Catenin Pathways. <i>Liver Cancer</i> , 2022, 11, 126-140.	4.2	3
16	Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2022, 40, 54-57.	0.2	2
17	Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 1038-1046.	1.8	17
18	Benign liver tumours: understanding molecular physiology to adapt clinical management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 703-716.	8.2	11

#	ARTICLE	IF	CITATIONS
19	Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. <i>Hepatology</i> , 2021, 73, 14-26.	3.6	66
20	The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 127-139.	2.6	21
21	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	7.7	28
22	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , 2021, 74, 1155-1166.	1.8	54
23	The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD. <i>Cancers</i> , 2021, 13, 411.	1.7	28
24	Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. <i>Communications Biology</i> , 2021, 4, 166.	2.0	19
25	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1554.	1.7	9
26	AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G543-G556.	1.6	5
27	Genomics of Viral Hepatitis-Associated Liver Tumors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1827.	1.0	7
28	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. <i>Cancer Discovery</i> , 2021, 11, 2524-2543.	7.7	41
29	Expression of NKG2D ligands is downregulated by β -catenin signalling and associates with HCC aggressiveness. <i>Journal of Hepatology</i> , 2021, 74, 1386-1397.	1.8	37
30	MicroRNAs Targeting HIF-2, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2 Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3099.	1.7	16
31	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2021, 13, 113.	3.6	31
32	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e382-e394.	0.9	9
33	Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2021, 81, 4910-4925.	0.4	30
34	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. <i>Hepatology</i> , 2021, 74, 816-834.	3.6	20
35	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. <i>Acta Oncologica</i> , 2021, 60, 1499-1506.	0.8	12
36	Direct, indirect and total effect of HIV coinfection on the risk of non-HIV-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. <i>HIV Medicine</i> , 2021, 22, 924-935.	1.0	2

#	ARTICLE	IF	CITATIONS
37	686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial. <i>Annals of Oncology</i> , 2021, 32, S704.	0.6	1
38	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 6.	18.1	2,757
39	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	3.6	129
40	<i>RSPO2</i> abnormal transcripts result from read-through in liver tumours with high β -catenin activation and <i>CTNNB1</i> mutations. <i>Gut</i> , 2020, 69, 1152-1153.	6.1	3
41	Polyploidy spectrum: a new marker in HCC classification. <i>Gut</i> , 2020, 69, 355-364.	6.1	82
42	Adeno-associated virus in the liver: natural history and consequences in tumour development. <i>Gut</i> , 2020, 69, 737-747.	6.1	78
43	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020, 69, 1667-1676.	6.1	17
44	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020, 72, 924-936.	1.8	44
45	Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ER α and HNF1 α . <i>Cancers</i> , 2020, 12, 2213.	1.7	4
46	Liver adenomatosis and NAFLD developed in the context of hereditary fructose intolerance. <i>Liver International</i> , 2020, 40, 3125-3126.	1.9	3
47	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. <i>PLoS ONE</i> , 2020, 15, e0238809.	1.1	5
48	LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. <i>Annals of Oncology</i> , 2020, 31, S1157.	0.6	26
49	Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib. <i>Kidney Cancer</i> , 2020, 4, 139-149.	0.2	0
50	New insights in the management of Hepatocellular Adenoma. <i>Liver International</i> , 2020, 40, 1529-1537.	1.9	18
51	Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. <i>Radiology</i> , 2020, 295, 361-372.	3.6	17
52	Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. <i>Molecular Oncology</i> , 2020, 14, 1207-1223.	2.1	74
53	Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 160-178.	3.6	36
54	Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. <i>Liver International</i> , 2019, 39, 136-146.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Dual Targeting of Histone Methyltransferase G9a and DNA Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 587-603.	3.6	81
56	PS-047-HSD17B13 loss of function variant protects from hepatocellular carcinoma developed on alcohol related liver disease. <i>Journal of Hepatology</i> , 2019, 70, e29-e30.	1.8	1
57	Natural history of liver adenomatosis: A long-term observational study. <i>Journal of Hepatology</i> , 2019, 71, 1184-1192.	1.8	32
58	ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 5859-5865.	3.2	64
59	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e909-e912.	0.9	1
60	From the Editor's desk. <i>Journal of Hepatology</i> , 2019, 71, 231-234.	1.8	0
61	Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. <i>Gastroenterology</i> , 2019, 157, 807-822.	0.6	22
62	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019, 157, 760-776.	0.6	141
63	The role of telomeres and telomerase in cirrhosis and liver cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 544-558.	8.2	154
64	Advanced clear-cell renal cell carcinoma (accRCC): Association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome. <i>Annals of Oncology</i> , 2019, 30, v394-v395.	0.6	0
65	From the Editor's Desk. <i>Journal of Hepatology</i> , 2019, 71, 853-855.	1.8	0
66	THU-456-Polyploidy spectrum: a new marker of molecular HCC tumour classification. <i>Journal of Hepatology</i> , 2019, 70, e360.	1.8	0
67	THU-374-The lncRNA H19-derived MIR-675 promotes liver necroptosis by targeting fadd. <i>Journal of Hepatology</i> , 2019, 70, e318.	1.8	0
68	THU-445-Beta-catenin signaling controls NKG2D ligands expression in liver tumorigenesis. <i>Journal of Hepatology</i> , 2019, 70, e354-e355.	1.8	0
69	FRI-465-The lncRNA H19 is an oncogenic driver of HCC in chronic inflammation-mediated mouse model. <i>Journal of Hepatology</i> , 2019, 70, e601-e602.	1.8	0
70	THU-452-TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e357-e358.	1.8	0
71	From the Editor's Desk. <i>Journal of Hepatology</i> , 2019, 71, 641-644.	1.8	0
72	Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β -Catenin Mutations. <i>Cell Metabolism</i> , 2019, 29, 1135-1150.e6.	7.2	92

#	ARTICLE	IF	CITATIONS
73	From the Editor's desk. Journal of Hepatology, 2019, 70, 1039-1042.	1.8	0
74	JHEP Reports: A new EASL open access journal. JHEP Reports, 2019, 1, 1.	2.6	0
75	From the Editor's desk. Journal of Hepatology, 2019, 71, 1-4.	1.8	0
76	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994.	0.9	34
77	Molecular and histological correlations in liver cancer. Journal of Hepatology, 2019, 71, 616-630.	1.8	308
78	From the Editor's desk. Journal of Hepatology, 2019, 70, 583-586.	1.8	0
79	From the Editor's desk. Journal of Hepatology, 2019, 70, 819-821.	1.8	0
80	A 17 β -Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. Hepatology, 2019, 70, 231-240.	3.6	75
81	Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nature Communications, 2019, 10, 1333.	5.8	125
82	Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 323-332.	1.8	11
83	<i>APC</i> germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Oncoimmunology, 2019, 8, e1583547.	2.1	31
84	From the Editor's desk..... Journal of Hepatology, 2019, 70, 335-338.	1.8	0
85	Journal of Hepatology: The Home of Liver Research, 2015-2019. Journal of Hepatology, 2019, 71, 1065-1069.	1.8	1
86	From the Editor's Desk. Journal of Hepatology, 2019, 71, 1061-1064.	1.8	0
87	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 58-65.	1.8	219
88	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 2019, 156, 492-509.	0.6	145
89	Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2019, 17, e235-e246.	0.9	4
90	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. International Journal of Cancer, 2019, 144, 533-544.	2.3	72

#	ARTICLE	IF	CITATIONS
91	Re: Molecular Subtypes of Clear-Cell Renal Cell Carcinoma are Prognostic for Outcome after Complete Metastasectomy. <i>Journal of Urology</i> , 2019, 201, 664-665.	0.2	0
92	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. <i>European Urology</i> , 2018, 74, 474-480.	0.9	72
93	Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 266-273.	0.9	11
94	From the Editor's desk.... <i>Journal of Hepatology</i> , 2018, 68, 377-379.	1.8	0
95	CHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. <i>Hepatology</i> , 2018, 68, 113-126.	3.6	244
96	Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. <i>Hepatology</i> , 2018, 68, 103-112.	3.6	159
97	From the Editor's desk.... <i>Journal of Hepatology</i> , 2018, 68, 1-4.	1.8	8
98	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. <i>Hepatology</i> , 2018, 68, 964-976.	3.6	43
99	From the Editor's desk..... <i>Journal of Hepatology</i> , 2018, 68, 631-634.	1.8	0
100	AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β -catenin activation. <i>Journal of Hepatology</i> , 2018, 68, 1203-1213.	1.8	78
101	Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. <i>Acta Oncologica</i> , 2018, 57, 498-508.	0.8	41
102	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e605-e612.	0.9	37
103	Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk. <i>Annals of Oncology</i> , 2018, 29, viii306-viii307.	0.6	5
104	From the Editor's desk. <i>Journal of Hepatology</i> , 2018, 69, 1209-1212.	1.8	0
105	microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. <i>Gastroenterology</i> , 2018, 155, 1951-1966.e26.	0.6	86
106	Cellular and Molecular Techniques. , 2018, , 88-110.		2
107	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , 2018, 9, 5235.	5.8	118
108	From the Editor's Desk. <i>Journal of Hepatology</i> , 2018, 69, 759-761.	1.8	0

#	ARTICLE	IF	CITATIONS
109	From the Editor's desk..... Journal of Hepatology, 2018, 69, 993-995.	1.8	0
110	Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma. Lung Cancer, 2018, 126, 15-24.	0.9	13
111	Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. New England Journal of Medicine, 2018, 379, 1178-1180.	13.9	15
112	Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. Journal of Hepatology, 2018, 69, 1074-1087.	1.8	31
113	Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics, 2018, 34, 3380-3381.	1.8	53
114	From the Editor's desk.... Journal of Hepatology, 2018, 68, 1107-1109.	1.8	1
115	Sigma 1 receptor: a potential actor in Hepato-Cellular Adenomas. Journal of Hepatology, 2018, 68, S48.	1.8	0
116	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology, 2018, 155, 431-442.e10.	0.6	81
117	From the Editor's desk..... Journal of Hepatology, 2018, 69, 1-4.	1.8	74
118	The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer, 2018, 18, 571.	1.1	8
119	From the Editor's desk..... Journal of Hepatology, 2018, 68, 869-872.	1.8	0
120	AAV2 viral infection in liver and tumor development. Journal of Hepatology, 2018, 68, S664-S665.	1.8	0
121	Corrigendum to "From the Editor's Desk August 2018" [J Hepatol 69 (2018) 265-268]. Journal of Hepatology, 2018, 69, 987.	1.8	0
122	From the Editor's desk..... Journal of Hepatology, 2018, 69, 559-561.	1.8	0
123	From the Editor's desk..... Journal of Hepatology, 2018, 69, 265-268.	1.8	1
124	Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell, 2018, 33, 1061-1077.e6.	7.7	151
125	From the Editor's desk.... Journal of Hepatology, 2017, 66, 1-4.	1.8	12
126	From the Editor's desk..... Journal of Hepatology, 2017, 66, 263-266.	1.8	0

#	ARTICLE	IF	CITATIONS
127	Mutational signature analysis identifies <i>MUTYH</i> deficiency in colorectal cancers and adrenocortical carcinomas. <i>Journal of Pathology</i> , 2017, 242, 10-15.	2.1	130
128	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2017, 23, 4364-4375.	3.2	57
129	From the Editor's desk.... <i>Journal of Hepatology</i> , 2017, 66, 1107-1110.	1.8	1
130	Malignant transformation of a β -catenin inflammatory adenoma due to an S45 β -catenin-activating mutation present 12 years before. <i>Human Pathology</i> , 2017, 62, 122-125.	1.1	13
131	Focal β -catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas. <i>Histopathology</i> , 2017, 71, 989-993.	1.6	14
132	From the Editor's desk.... <i>Journal of Hepatology</i> , 2017, 67, 1-4.	1.8	5
133	A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases. <i>Hepatology</i> , 2017, 66, 1644-1661.	3.6	15
134	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. <i>Journal of Hepatology</i> , 2017, 67, 727-738.	1.8	525
135	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification. <i>Journal of Hepatology</i> , 2017, 66, S462.	1.8	1
136	From the Editor's desk.... <i>Journal of Hepatology</i> , 2017, 66, 469-472.	1.8	0
137	From the Editor's desk..... <i>Journal of Hepatology</i> , 2017, 66, 671-674.	1.8	1
138	RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. <i>Cancer Cell</i> , 2017, 31, 94-109.	7.7	115
139	Co-occurring Mutations of Tumor Suppressor Genes, <i>LATS2</i> and <i>NF2</i> , in Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 3191-3202.	3.2	67
140	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. <i>Journal of Hepatology</i> , 2017, 66, 734-742.	1.8	31
141	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
142	Reply. <i>Hepatology</i> , 2017, 66, 2093-2094.	3.6	1
143	From the Editor's desk.... <i>Journal of Hepatology</i> , 2017, 67, 659-662.	1.8	0
144	From the Editor's desk.... <i>Journal of Hepatology</i> , 2017, 67, 889-892.	1.8	0

#	ARTICLE	IF	CITATIONS
145	From the Editor's desk.... Journal of Hepatology, 2017, 67, 437-440.	1.8	0
146	Molecular classification of hepatocellular adenoma in clinical practice. Journal of Hepatology, 2017, 67, 1074-1083.	1.8	119
147	From the Editor's desk.... Journal of Hepatology, 2017, 67, 207-210.	1.8	0
148	Note of caution: Contaminations of hepatocellular cell lines. Journal of Hepatology, 2017, 67, 896-897.	1.8	37
149	From the Editor's desk.... Journal of Hepatology, 2017, 67, 1125-1128.	1.8	0
150	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nature Communications, 2017, 8, 1315.	5.8	228
151	aCNViewer: Comprehensive genome-wide visualization of absolute copy number and copy neutral variations. PLoS ONE, 2017, 12, e0189334.	1.1	5
152	Hepatocyte nuclear factor 1 α suppresses steatosis-associated liver cancer by inhibiting PPAR γ transcription. Journal of Clinical Investigation, 2017, 127, 1873-1888.	3.9	58
153	Metalloproteinase meprin 1 α regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin. Oncotarget, 2017, 8, 7839-7851.	0.8	20
154	Metastatic clear cell renal cell carcinoma: Proangiogenic gene expression and outcome on sunitinib.. Journal of Clinical Oncology, 2017, 35, e16085-e16085.	0.8	0
155	The liver-specific microRNA miR-122*, the complementary strand of microRNA miR-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. Hepatology, 2016, 64, 1623-1636.	3.6	48
156	Hepatocellular adenoma with malignant transformation in a patient with neonatal portal vein thrombosis. Hepatology, 2016, 64, 675-677.	3.6	10
157	Genotype-phenotype correlation of CTNNB1 mutations reveals different Wnt/catenin activity associated with liver tumor progression. Hepatology, 2016, 64, 2047-2061.	3.6	222
158	Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point mutant β -catenin. Hepatology, 2016, 64, 1587-1605.	3.6	92
159	From the Editor's desk..... Journal of Hepatology, 2016, 65, 1073-1076.	1.8	0
160	Reply. Hepatology, 2016, 63, 342-342.	3.6	0
161	From the Editor's desk.... Journal of Hepatology, 2016, 64, 1199-1202.	1.8	0
162	From the Editor's desk.... Journal of Hepatology, 2016, 64, 759-762.	1.8	0

#	ARTICLE	IF	CITATIONS
163	Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease. <i>Journal of Hepatology</i> , 2016, 65, 552-559.	1.8	32
164	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. <i>Nature Medicine</i> , 2016, 22, 744-753.	15.2	207
165	PNPLA3 gene in liver diseases. <i>Journal of Hepatology</i> , 2016, 65, 399-412.	1.8	205
166	Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1095271.	0.3	12
167	Mechanisms of HBV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, S84-S101.	1.8	664
168	EASL Clinical Practice Guidelines on the management of benign liver tumours. <i>Journal of Hepatology</i> , 2016, 65, 386-398.	1.8	372
169	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. <i>Molecular Therapy</i> , 2016, 24, 660-661.	3.7	33
170	Genotype-Phenotype Correlation of CTNNB1 Mutations Reveals Different B-Catenin Activation Levels in Hepatocellular Tumors with High Activity Associated with Malignancy. <i>Journal of Hepatology</i> , 2016, 64, S578.	1.8	1
171	From the Editor's desk.... <i>Journal of Hepatology</i> , 2016, 65, 1-4.	1.8	2
172	TGF- β 1 promotes linear invadosome formation in hepatocellular carcinoma cells, through DDR1 up-regulation and collagen I cross-linking. <i>European Journal of Cell Biology</i> , 2016, 95, 503-512.	1.6	41
173	From the Editor's desk. <i>Journal of Hepatology</i> , 2016, 65, 457-461.	1.8	1
174	From the Editor's desk.... <i>Journal of Hepatology</i> , 2016, 65, 233-236.	1.8	0
175	From the Editor's desk.... <i>Journal of Hepatology</i> , 2016, 65, 657-660.	1.8	0
176	Validation of VEGFR rs9582036 as predictive biomarker in metastatic clear cell renal cell carcinoma patients treated with sunitinib. <i>BJU International</i> , 2016, 118, 890-901.	1.3	23
177	From the Editor's desk.... <i>Journal of Hepatology</i> , 2016, 65, 869-872.	1.8	0
178	Genomic Signatures of Risk Factors and Molecular Identification of HCC Subtypes. , 2016, , 113-119.		0
179	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	18.1	1,863
180	From the Editor's desk.... <i>Journal of Hepatology</i> , 2016, 64, 1-4.	1.8	7

#	ARTICLE	IF	CITATIONS
181	The transcriptomic G1â€“G6 signature of hepatocellular carcinoma in an Asian population. <i>Medicine (United States)</i> , 2016, 95, e5263.	0.4	6
182	From the Editorâ€™s desk.... <i>Journal of Hepatology</i> , 2016, 64, 991-995.	1.8	0
183	Translating the molecular diversity of hepatocellular carcinoma into clinical practice. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1057316.	0.3	3
184	From the Editorâ€™s desk.... <i>Journal of Hepatology</i> , 2016, 64, 253-256.	1.8	0
185	From the Editorâ€™s desk.... <i>Journal of Hepatology</i> , 2016, 64, 527-531.	1.8	0
186	AAV2 and Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 2016, 27, 211-213.	1.4	8
187	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	1.1	160
188	Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. <i>Modern Pathology</i> , 2016, 29, 43-50.	2.9	45
189	TERT promoter mutations in primary liver tumors. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 9-14.	0.7	78
190	Abstract IA20: Cancer subtypes and their immune microenvironments. , 2016, , .		0
191	Abstract 3666: Co-occurring mutations of tumors suppressor genes, NF2 and LATS2, in malignant pleural mesothelioma. , 2016, , .		0
192	Abstract 112: Genetic alterations in molecular tumor subgroups of malignant pleural mesothelioma. , 2016, , .		1
193	Abstract 1257: A MYC-Aurka protein complex represents an actionable target in p53 altered liver cancer. , 2016, , .		0
194	Abstract IA10: Tumor microenvironments: Prognostic and theranostic impacts. , 2016, , .		0
195	P0266 : Adeno-Associated Virus 2 (AAV2) induces recurrent insertional mutagenesis in Human Hepatocellular Carcinomas. <i>Journal of Hepatology</i> , 2015, 62, S406.	1.8	1
196	From the Editorâ€™s desk.... <i>Journal of Hepatology</i> , 2015, 63, 1-4.	1.8	3
197	From the Editorâ€™s deskâ€¦. <i>Journal of Hepatology</i> , 2015, 63, 775-777.	1.8	0
198	From the Editorâ€™s desk.... <i>Journal of Hepatology</i> , 2015, 63, 1057-1061.	1.8	0

#	ARTICLE	IF	CITATIONS
199	BRAF V600E mutations in bile duct adenomas. <i>Hepatology</i> , 2015, 61, 403-405.	3.6	19
200	From the Editor's desk.... <i>Journal of Hepatology</i> , 2015, 63, 1299-1302.	1.8	0
201	From the Editor's desk . <i>Journal of Hepatology</i> , 2015, 62, 991-994.	1.8	0
202	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>Oncolimmunology</i> , 2015, 4, e1049804.	2.1	51
203	RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. <i>British Journal of Cancer</i> , 2015, 113, 1313-1322.	2.9	19
204	Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease. <i>Hepatic Oncology</i> , 2015, 2, 63-78.	4.2	2
205	DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	3.6	367
206	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	0.6	109
207	A gp130 Src-YAP module links inflammation to epithelial regeneration. <i>Nature</i> , 2015, 519, 57-62.	13.7	528
208	Toward understanding and exploiting tumor heterogeneity. <i>Nature Medicine</i> , 2015, 21, 846-853.	15.2	604
209	P0265 : IGF2 is an oncogenic driver in HCC and emerges as a potential target for therapies. <i>Journal of Hepatology</i> , 2015, 62, S405-S406.	1.8	0
210	From the Editor's desk.... <i>Journal of Hepatology</i> , 2015, 62, 1221-1224.	1.8	0
211	Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 499-506.	3.2	42
212	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 1226-1239.e4.	0.6	980
213	Authors' response: virus-host interactions in HBV-related hepatocellular carcinoma: more to be revealed?. <i>Gut</i> , 2015, 64, 853-854.	6.1	11
214	Well-differentiated hepatocellular neoplasm of uncertain malignant potential. <i>Human Pathology</i> , 2015, 46, 634-635.	1.1	22
215	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. <i>Clinical Cancer Research</i> , 2015, 21, 1329-1339.	3.2	250
216	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372

#	ARTICLE	IF	CITATIONS
217	NRF2/KEAP1 and Wnt/ β -catenin in the multistep process of liver carcinogenesis in humans and rats. <i>Hepatology</i> , 2015, 62, 677-679.	3.6	20
218	P0480 : Role of the immune microenvironment during hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, S494.	1.8	0
219	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. <i>Nature Genetics</i> , 2015, 47, 1187-1193.	9.4	387
220	Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. <i>Hepatic Oncology</i> , 2015, 2, 291-302.	4.2	6
221	Single nucleotide polymorphisms in mRCCâ€”is their time up?. <i>Nature Reviews Urology</i> , 2015, 12, 424-426.	1.9	4
222	Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e407-e410.	0.9	1
223	From the Editor's Desk <i>Journal of Hepatology</i> , 2015, 62, 6-7.	1.8	7
224	From the Editorâ€™s desk.... <i>Journal of Hepatology</i> , 2015, 63, 537-539.	1.8	0
225	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. <i>Gut</i> , 2015, 64, 820-829.	6.1	127
226	Molecular subtypes and prognosis in RCC. <i>Aging</i> , 2015, 7, 219-220.	1.4	0
227	Abstract 2973: Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets. , 2015, , .		0
228	Abstract 919: Adeno-associated virus 2 (AAV2) induces recurrent insertional mutagenesis in human hepatocellular carcinomas. , 2015, , .		0
229	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Acta OncolÃ³gica</i> , 2014, 53, 1413-1422.	0.8	30
230	Physiopathology of Hepatocellular Carcinoma. , 2014, , 1881-1886.		1
231	Integrative Quantitative Proteomics Unveils Proteostasis Imbalance in Human Hepatocellular Carcinoma Developed on Nonfibrotic Livers. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3473-3483.	2.5	15
232	Prognostic impact of baseline serum α -reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. <i>BJU International</i> , 2014, 114, 81-89.	1.3	68
233	Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2014, 20, 1323-1334.	3.2	121
234	High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression. <i>Brain Pathology</i> , 2014, 24, 184-189.	2.1	209

#	ARTICLE	IF	CITATIONS
235	VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. <i>Acta Oncologica</i> , 2014, 53, 103-112.	0.8	45
236	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. <i>Seminars in Liver Disease</i> , 2014, 34, 363-375.	1.8	47
237	Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. <i>Oncogene</i> , 2014, 33, 3748-3752.	2.6	68
238	Overexpression of phosphatidylinositol 4-kinase type III α is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma. <i>BMC Cancer</i> , 2014, 14, 7.	1.1	19
239	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	7.7	240
240	Genomic portrait of resectable hepatocellular carcinomas: Implications of <i>RB1</i> and <i>FGF19</i> aberrations for patient stratification. <i>Hepatology</i> , 2014, 60, 1972-1982.	3.6	345
241	Characterization of a novel PXR isoform with potential dominant-negative properties. <i>Journal of Hepatology</i> , 2014, 61, 609-616.	1.8	15
242	ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ β -catenin pathway. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 53-60.	1.4	25
243	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. <i>Hepatology</i> , 2014, 60, 1983-1992.	3.6	268
244	Genetics of hepatocellular carcinoma: The next generation. <i>Journal of Hepatology</i> , 2014, 60, 224-226.	1.8	59
245	Abstract 1609: Proline-directed kinase signaling in human hepatocellular carcinomas developed on non-fibrotic liver. , 2014, , .		0
246	Use of Molecular Biology for Identifying Benign Hepatocellular Tumors Leads to More Personalized Medicine. <i>MD Conference Express</i> , 2014, 14, 6-8.	0.0	0
247	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	13.7	8,060
248	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. <i>Nature Communications</i> , 2013, 4, 2218.	5.8	513
249	A functional screening identifies five micrnas controlling glypican-3: role of mir-1271 down-regulation in hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 195-204.	3.6	76
250	Benign hepatocellular nodules: What have we learned using the patho-molecular classification. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 322-327.	0.7	26
251	Hepatocellular Benign Tumors – From Molecular Classification to Personalized Clinical Care. <i>Gastroenterology</i> , 2013, 144, 888-902.	0.6	251
252	Primary Liver Carcinomas Can Originate From Different Cell Types: A New Level of Complexity in Hepatocarcinogenesis. <i>Gastroenterology</i> , 2013, 145, 53-55.	0.6	10

#	ARTICLE	IF	CITATIONS
253	Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. <i>Hepatology</i> , 2013, 58, 229-238.	3.6	172
254	Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. <i>British Journal of Cancer</i> , 2013, 108, 887-900.	2.9	88
255	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. <i>Journal of Hepatology</i> , 2013, 58, 350-357.	1.8	146
256	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	0.6	302
257	Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. <i>International Journal of Hepatology</i> , 2013, 2013, 1-12.	0.4	52
258	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. <i>Oncolmmunology</i> , 2013, 2, e27090.	2.1	39
259	Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. <i>Mutagenesis</i> , 2013, 28, 323-331.	1.0	35
260	Recurrent inactivating mutations of <i>ARID2</i> in non-small cell lung carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 2217-2221.	2.3	70
261	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 639-651.	0.8	34
262	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	1.7	50
263	Double Heterozygous Germline HNF1A Mutations in a Patient With Liver Adenomatosis. <i>Diabetes Care</i> , 2012, 35, e35-e35.	4.3	11
264	Immunohistochemical Markers on Needle Biopsies Are Helpful for the Diagnosis of Focal Nodular Hyperplasia and Hepatocellular Adenoma Subtypes. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1691-1699.	2.1	118
265	KIF20A mRNA and Its Product MKlp2 Are Increased During Hepatocyte Proliferation and Hepatocarcinogenesis. <i>American Journal of Pathology</i> , 2012, 180, 131-140.	1.9	76
266	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. <i>Journal of Hepatology</i> , 2012, 56, 184-191.	1.8	354
267	Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. <i>Journal of Hepatology</i> , 2012, 56, 869-876.	1.8	53
268	Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 663-674.	1.8	140
269	CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. <i>European Journal of Cancer</i> , 2012, 48, 138-148.	1.3	68
270	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. <i>Nature Genetics</i> , 2012, 44, 694-698.	9.4	1,229

#	ARTICLE	IF	CITATIONS
271	Role of Contrast-Enhanced Sonography in Differentiation of Subtypes of Hepatocellular Adenoma: Correlation with MRI Findings. <i>American Journal of Roentgenology</i> , 2012, 199, 341-348.	1.0	58
272	Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. <i>Oncology</i> , 2012, 1, 1612-1613.	2.1	24
273	Genotype-Phenotype Relationships in Hepatocellular Carcinoma: p53 Inactivation Promotes Tumors With Stem Cell Features. <i>Gastroenterology</i> , 2012, 142, 1066-1069.	0.6	3
274	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncology</i> , 2012, 1, 28-37.	2.1	103
275	Dual Blockade of Epidermal Growth Factor Receptor-Induced Pathways: A New Avenue to Treat Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1550-1552.	0.8	8
276	Rnd3/RhoE Is down-regulated in hepatocellular carcinoma and controls cellular invasion. <i>Hepatology</i> , 2012, 55, 1766-1775.	3.6	53
277	When activated oncogene meets immunity: A fight to prevent liver tumor initiation. <i>Hepatology</i> , 2012, 56, 387-389.	3.6	1
278	Synchronous hepatocellular carcinoma and Castleman's disease: The role of the interleukin-6-signaling pathway. <i>Hepatology</i> , 2012, 56, 392-393.	3.6	10
279	Abstract 5121: Acquired inactivating ARID2 mutations in lung non small cell carcinoma. , 2012, , .		0
280	A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression. <i>Journal of the National Cancer Institute</i> , 2011, 103, 47-60.	3.0	66
281	Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma. <i>American Journal of Pathology</i> , 2011, 178, 881-894.	1.9	48
282	Will the pathomolecular classification of hepatocellular adenomas improve their clinical management?. <i>Journal of Hepatology</i> , 2011, 55, 8-10.	1.8	11
283	Fighting the bushfire in HCC trials. <i>Journal of Hepatology</i> , 2011, 55, 276-277.	1.8	20
284	Re: A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression. <i>Journal of Urology</i> , 2011, 186, 456-456.	0.2	0
285	Familial liver adenomatosis. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , .	0.1	0
286	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011, 2, 66.	2.2	9
287	HNF1 α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines. <i>BMC Cancer</i> , 2011, 11, 427.	1.1	35
288	Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. <i>Liver Transplantation</i> , 2011, 17, S67-S71.	1.3	20

#	ARTICLE	IF	CITATIONS
289	The <i>HOX</i> gene network in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 2577-2587.	2.3	60
290	Genetics of Hepatobiliary Carcinogenesis. <i>Seminars in Liver Disease</i> , 2011, 31, 173-187.	1.8	138
291	Revisiting the Pathology of Resected Benign Hepatocellular Nodules Using New Immunohistochemical Markers. <i>Seminars in Liver Disease</i> , 2011, 31, 091-103.	1.8	112
292	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. <i>Journal of Experimental Medicine</i> , 2011, 208, 1359-1366.	4.2	218
293	Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. <i>Annals of Oncology</i> , 2011, 22, 794-800.	0.6	116
294	Benign Liver Tumors. <i>Molecular Pathology Library</i> , 2011, , 769-775.	0.1	1
295	Liver adenoma. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , .	0.1	0
296	Focal nodular hyperplasia, hepatocellular adenomas: Past, present, future. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 355-358.	0.9	29
297	Loss of hepatocyte nuclear factor 1 \pm function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. <i>Hepatology</i> , 2010, 51, 557-566.	3.6	66
298	Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins. <i>Liver International</i> , 2010, 30, 149-154.	1.9	20
299	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	13.7	2,114
300	Focal nodular hyperplasia with major sinusoidal dilatation: a misleading entity. <i>BMJ Case Reports</i> , 2010, 2010, bcr0920103311-bcr0920103311.	0.2	10
301	R36: Sous-expression de Rnd3/RhoE dans le carcinome h�patocellulaire : implication dans l�invasion des h�patocytes tumoraux. <i>Bulletin Du Cancer</i> , 2010, 97, S29-S30.	0.6	1
302	Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying <i>NF2</i> Status. <i>Clinical Cancer Research</i> , 2010, 16, 4155-4164.	3.2	103
303	Inactivation of the <i>APC</i> Gene Is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis but Not Frequent in Sporadic Adrenocortical Cancers. <i>Clinical Cancer Research</i> , 2010, 16, 5133-5141.	3.2	97
304	Subtype Classification of Hepatocellular Adenoma. <i>Digestive Surgery</i> , 2010, 27, 39-45.	0.6	143
305	Spectrum of <i>HNF1A</i> Somatic Mutations in Hepatocellular Adenoma Differs From That in Patients With <i>MODY3</i> and Suggests Genotoxic Damage. <i>Diabetes</i> , 2010, 59, 1836-1844.	0.3	57
306	Identification of Novel Oncogenes and Tumor Suppressors in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2010, 30, 075-086.	1.8	75

#	ARTICLE	IF	CITATIONS
307	Comment on: How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?. Digestive and Liver Disease, 2010, 42, 234-235.	0.4	1
308	p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer, 2010, 67, 23-30.	0.9	50
309	An adult male patient with multiple adenomas and a hepatocellular carcinoma: Mild Glycogen Storage Disease type Ia. Journal of Hepatology, 2010, 53, 213-217.	1.8	40
310	Building a bridge between obesity, inflammation and liver carcinogenesis. Journal of Hepatology, 2010, 53, 777-779.	1.8	7
311	Molecular classification of hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S235-S241.	0.4	73
312	Gene Mutations and Transcriptomic Profiles Associated to Specific Subtypes of Hepatocellular Tumors. , 2010, , 259-275.		0
313	Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience. Hepatology, 2009, 50, 481-489.	3.6	394
314	Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. Hepatology, 2009, 50, 1871-1883.	3.6	54
315	What's in a name?. Hepatology, 2009, 51, NA-NA.	3.6	5
316	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 2009, 457, 200-204.	13.7	437
317	Overexpression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver International, 2009, 29, 459-465.	1.9	143
318	Hepatocellular adenoma: what is new in 2008. Hepatology International, 2008, 2, 316-321.	1.9	78
319	MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 2008, 47, 1955-1963.	3.6	634
320	Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification. Hepatology, 2008, 48, 808-818.	3.6	277
321	Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. Journal of Hepatology, 2008, 48, 163-170.	1.8	235
322	Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations. Journal of Hepatology, 2008, 48, 884-886.	1.8	5
323	The β -catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. Journal of Hepatology, 2008, 49, 61-71.	1.8	87
324	Prognostic Significance of SALL4 Expression Levels in Paediatric Acute Myeloid Leukaemia (AML).. Blood, 2008, 112, 2243-2243.	0.6	1

#	ARTICLE	IF	CITATIONS
325	Association of CYP1B1 Germ Line Mutations with Hepatocyte Nuclear Factor 1 α Mutated Hepatocellular Adenoma. <i>Cancer Research</i> , 2007, 67, 2611-2616.	0.4	62
326	Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. <i>Pharmacogenomics</i> , 2007, 8, 997-1003.	0.6	33
327	Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. <i>European Journal of Endocrinology</i> , 2007, 156, 617-621.	1.9	34
328	HNF1 α Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation. <i>Journal of Biological Chemistry</i> , 2007, 282, 14437-14446.	1.6	123
329	Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. <i>Journal of Hepatology</i> , 2007, 46, 521-527.	1.8	170
330	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. <i>Hepatology</i> , 2007, 45, 42-52.	3.6	1,034
331	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. <i>Hepatology</i> , 2007, 46, 740-748.	3.6	554
332	Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. <i>Hepatology</i> , 2007, 46, 1108-1118.	3.6	100
333	Differential effects of inactivated Axin1 and activated β -catenin mutations in human hepatocellular carcinomas. <i>Oncogene</i> , 2007, 26, 774-780.	2.6	230
334	Loss of Trim24 (Tif1 α) gene function confers oncogenic activity to retinoic acid receptor alpha. <i>Nature Genetics</i> , 2007, 39, 1500-1506.	9.4	145
335	Genotype phenotype classification of hepatocellular adenoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 2649.	1.4	90
336	Hepatocellular adenoma displaying a HNF1 α inactivation in a patient with familial adenomatous polyposis coli. <i>Journal of Hepatology</i> , 2006, 45, 883-886.	1.8	28
337	Genetics of hepatocellular tumors. <i>Oncogene</i> , 2006, 25, 3778-3786.	2.6	304
338	Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. <i>Hepatology</i> , 2006, 43, 515-524.	3.6	733
339	Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. <i>Oncogene</i> , 2005, 24, 7253-7256.	2.6	36
340	Absence of KLF6 gene mutation in 71 hepatocellular carcinomas. <i>Hepatology</i> , 2005, 41, 681-682.	3.6	31
341	Germline hepatocyte nuclear factor 1 α and 1 β mutations in renal cell carcinomas. <i>Human Molecular Genetics</i> , 2005, 14, 603-614.	1.4	109
342	Similar Tumor Suppressor Gene Alteration Profiles in Asbestos-Induced Murine and Human Mesothelioma. <i>Cell Cycle</i> , 2005, 4, 1862-1869.	1.3	45

#	ARTICLE	IF	CITATIONS
343	Mutation of TP53 gene is involved in carcinogenesis of hepatic undifferentiated (embryonal) sarcoma of the adult, in contrast with Wnt or telomerase pathways: an immunohistochemical study of three cases with genomic relation in two cases. <i>Journal of Hepatology</i> , 2005, 42, 424-429.	1.8	32
344	Clinical, Morphologic, and Molecular Features Defining So-Called Telangiectatic Focal Nodular Hyperplasias of the Liver. <i>Gastroenterology</i> , 2005, 128, 1211-1218.	0.6	207
345	Hepatocyte Nuclear Factor-1 α Gene Inactivation: Cosegregation between Liver Adenomatosis and Diabetes Phenotypes in Two Maturity-Onset Diabetes of the Young (MODY)3 Families. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1476-1480.	1.8	124
346	Mutation of TCF1 encoding hepatocyte nuclear factor 1 α in gynecological cancer. <i>Oncogene</i> , 2004, 23, 7588-7592.	2.6	21
347	Genetic alterations in hepatocellular adenomas: recent findings and new challenges. <i>Journal of Hepatology</i> , 2004, 40, 1036-1039.	1.8	33
348	Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. <i>Journal of Hepatology</i> , 2004, 41, 292-298.	1.8	126
349	Genetic alterations in hepatocellular adenomas. <i>Hepatology</i> , 2003, 37, 480-480.	3.6	9
350	Familial liver adenomatosis associated with hepatocyte nuclear factor 1 α inactivation1 The authors thank Leigh Pascoe for critical reading of the manuscript, H�ne Blanch� and Hung Bui of the CEPH/Fondation Jean Dausset for technical help in sequencing, and Drs. A. Saillant, E. Akodjenou, and E. Urvoas (Pediatric and Radiology Units, H�pitaux de Chartres, France) for referring patient B1 to E.J. and for performing liver ultrasound screening in family B.. <i>Gastroenterology</i> , 2003, 125, 1470-1475.	0.6	169
351	Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. <i>Gastroenterology</i> , 2003, 124, 1311-1314.	0.6	23
352	The identification of small nodules in liver adenomatosis. <i>Journal of Hepatology</i> , 2003, 39, 77-85.	1.8	42
353	HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. <i>Blood</i> , 2002, 100, 991-997.	0.6	125
354	Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. <i>Oncogene</i> , 2002, 21, 1225-1232.	2.6	65
355	Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2002, 21, 5016-5023.	2.6	17
356	Bi-allelic inactivation of TCF1 in hepatic adenomas. <i>Nature Genetics</i> , 2002, 32, 312-315.	9.4	333
357	Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma. <i>Oncogene</i> , 2001, 20, 5232-5238.	2.6	45
358	High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. <i>Human Molecular Genetics</i> , 2001, 10, 271-282.	1.4	147
359	NF2 gene deletion in a family with a mild phenotype. <i>Journal of Medical Genetics</i> , 2000, 37, 75-77.	1.5	12
360	Molecular Characterization of Germline NF2 Gene Rearrangements. <i>Genomics</i> , 2000, 65, 62-66.	1.3	22

#	ARTICLE	IF	CITATIONS
361	Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. <i>Cancer Research</i> , 2000, 60, 707-11.	0.4	62
362	PCR-Based Genotyping Can Generate Artifacts in LOH Analyses. <i>BioTechniques</i> , 1999, 27, 1100-1102.	0.8	13
363	Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. <i>Oncogene</i> , 1999, 18, 4044-4046.	2.6	149
364	Characterisation of 16 polymorphic markers in the NF2 gene: Application to hemizyosity detection. <i>Human Mutation</i> , 1999, 13, 290-293.	1.1	27
365	Cryptic Exons as a Source of Increased Diversity of Ewing Tumor-Associated EWS-FLI1 Chimeric Products. <i>Genomics</i> , 1999, 60, 371-374.	1.3	13
366	Characterisation of 16 polymorphic markers in the NF2 gene: Application to hemizyosity detection. <i>Human Mutation</i> , 1999, 13, 290.	1.1	2
367	NF2 gene in neurofibromatosis type 2 patients. <i>Human Molecular Genetics</i> , 1998, 7, 2095-2101.	1.4	69
368	Chromosome translocation based on illegitimate recombination in human tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 11786-11791.	3.3	101
369	Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination. <i>Human Genetics</i> , 1997, 99, 357-363.	1.8	51
370	LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. , 1997, 18, 232-239.		38
371	Identification of New Members of the Gas2 and Ras Families in the 22q12 Chromosome Region. <i>Genomics</i> , 1996, 38, 247-254.	1.3	50
372	Cloning of a balanced translocation breakpoint in the DiGeorge syndrome critical region and isolation of a novel potential adhesion receptor gene in its vicinity. <i>Human Molecular Genetics</i> , 1995, 4, 551-558.	1.4	69
373	Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. <i>Human Molecular Genetics</i> , 1995, 4, 2219-2226.	1.4	190
374	Cloning of the entire FLI1 gene, disrupted by the Ewing's Sarcoma translocation breakpoint on 11q24, in a yeast artificial chromosome. <i>Cytogenetic and Genome Research</i> , 1994, 67, 129-136.	0.6	11
375	The Ewing Family of Tumors – A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts. <i>New England Journal of Medicine</i> , 1994, 331, 294-299.	13.9	1,010
376	Precise localization on chromosome 12 of the ATF-1 gene by fluorescence in situ hybridization. <i>Human Genetics</i> , 1994, 93, 207-8.	1.8	4
377	p53 mutations in human tumors with chimeric EWS/FLI/1 genes. <i>International Journal of Cancer</i> , 1994, 57, 336-340.	2.3	49
378	Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. <i>Cancer Genetics and Cytogenetics</i> , 1994, 74, 13-18.	1.0	67

#	ARTICLE	IF	CITATIONS
379	Neurofibromatosis type 2. <i>European Journal of Cancer</i> , 1994, 30, 1981-1987.	1.3	16
380	Genetic Alterations in the Chromosome 22q12 Region Associated with Development of Neuroectodermal Tumors. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1994, 59, 555-564.	2.0	1
381	Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. <i>Nature</i> , 1993, 363, 515-521.	13.7	1,351
382	EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. <i>Nature Genetics</i> , 1993, 4, 341-345.	9.4	483
383	Mapping of Human $\hat{1}^3$ -Glutamyl Transpeptidase Genes on Chromosome 22 and Other Human Autosomes. <i>Genomics</i> , 1993, 17, 299-305.	1.3	36
384	Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. <i>Genomics</i> , 1993, 18, 609-615.	1.3	94
385	Dinucleotide repeat polymorphism at the D22S268 locus. <i>Human Molecular Genetics</i> , 1993, 2, 336-336.	1.4	28
386	Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 5752-5756.	3.3	538
387	Assignment of the human stromelysin 3 (STMY3) gene to the q11.2 region of chromosome 22. <i>Genomics</i> , 1992, 13, 881-883.	1.3	32
388	Rapid isolation of cosmids from defined subregions by differential Alu-PCR hybridization on chromosome 22-specific library. <i>Genomics</i> , 1992, 13, 395-401.	1.3	14
389	In situ hybridization of PCR amplified inter-Alu sequences from a hybrid cell line. <i>Human Genetics</i> , 1992, 88, 541-544.	1.8	6
390	Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. <i>Nature</i> , 1992, 359, 162-165.	13.7	1,724
391	Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. <i>Genes Chromosomes and Cancer</i> , 1992, 5, 30-34.	1.5	48
392	Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. <i>Genes Chromosomes and Cancer</i> , 1992, 5, 271-277.	1.5	284
393	Mapping of human chromosome 22 with a panel of somatic cell hybrids. <i>Genomics</i> , 1991, 9, 721-727.	1.3	60
394	Organization and expression of the $\hat{1}^3$ -like genes that contribute to the $\hat{1}^3/4$ - $\hat{1}^1$ light chain complex in human pre-B cells. <i>International Immunology</i> , 1991, 3, 1081-1090.	1.8	38